{"url":"https://newsforagent.com/news/2026-11-03/delveinsight-sickle-cell-pipeline-report","markdown_url":"https://newsforagent.com/news/2026-11-03/delveinsight-sickle-cell-pipeline-report.md","title":"DelveInsight Maps 45+ Sickle Cell Drug Developers","headline":"DelveInsight Report Counts 45+ Companies and 50+ Drugs in Sickle Cell Pipeline","description":"DelveInsight's 2026 sickle cell report counts 45+ companies and 50+ drugs, with about 5 in late-stage development and mitapivat under FDA priority review.","section":"Research & Clinical Trials","published_at":"2026-11-03T18:14:28+00:00","modified_at":"2026-11-03T18:14:28+00:00","author":"News Desk","key_takeaways":["DelveInsight's 2026 sickle cell report covers 45+ active companies developing 50+ pipeline drugs.","About 5 sickle cell drugs sit in late-stage development, including Agios's mitapivat under a Priority Review with a November 1, 2026 PDUFA goal date.","CorrectSequence Therapeutics' CS-206 kept a patient in China free of vaso-occlusive crises for more than 15 months after engraftment."],"companies":[{"name":"DelveInsight","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00056iy/delveinsight","website":"https://www.delveinsight.com"},{"name":"CorrectSequence Therapeutics","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00031tf/correctsequence-therapeutics","website":"http://www.correctsequence.com/?lang=en"},{"name":"Vertex Pharmaceuticals","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00004y4/vertex-pharmaceuticals","website":"http://www.vrtx.com"}],"source":{"publisher":"GlobeNewswire","title":"Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight","url":"https://www.globenewswire.com/news-release/2026/11/03/3394662/0/en/sickle-cell-disease-clinical-trial-pipeline-gains-momentum-45-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight.html"},"other_sources":[],"tags":["Research & Clinical Trials","DelveInsight","CorrectSequence Therapeutics","Vertex Pharmaceuticals"],"body_markdown":"[DelveInsight](https://akta.pro/company-profiles/00056iy/delveinsight)'s 2026 sickle cell disease pipeline report counts 45+ active companies developing 50+ drugs, with about 5 in late-stage development. The New York-based research firm published the analysis on November 3, 2026, [according to GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/03/3394662/0/en/sickle-cell-disease-clinical-trial-pipeline-gains-momentum-45-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight.html).\n\n## What DelveInsight's Sickle Cell Report Covers\n\nThe report spans pipeline therapies across discovery, preclinical, Phase I, Phase II and Phase III, and tracks regulatory pathways involving the FDA and EMA. Named developers include Novo Nordisk, Novartis, [CorrectSequence Therapeutics](https://akta.pro/company-profiles/00031tf/correctsequence-therapeutics), Disc Medicine, CSL Behring, Sanofi, Bristol-Myers Squibb, Beam Therapeutics, [Vertex Pharmaceuticals](https://akta.pro/company-profiles/00004y4/vertex-pharmaceuticals) and others. Listed therapies include etavopivat, rilzabrutinib, BEAM-101, CS-206 and DISC-3405.\n\nStuti Mahajan, Functional Head of Consulting at DelveInsight, said the sickle cell market is expected to shift toward more targeted and disease-modifying therapies, supported by the advancement of oral metabolic therapies, gene therapies, and fetal hemoglobin–inducing approaches. \"Positive Phase III data for etavopivat and the regulatory progress of mitapivat could expand pharmacological treatment options, while programs such as BEAM-101 and CS-206 may drive longer-term disease modification,\" Mahajan said.\n\nCorrectSequence Therapeutics said in June 2026 that the first sickle cell patient treated in China with its base-editing therapy CS-206 remained free of vaso-occlusive crises for more than 15 months after engraftment. A Cell Stem Cell study published on September 7, 2026, reported that tBE-mediated base editing therapy achieved durable clinical remission in sickle cell disease and thalassemia patients across diverse genetic backgrounds, FinanzNachrichten.de reported.\n\n## DelveInsight's Research Business\n\nDelveInsight was founded in 2014 and is headquartered in New Delhi, with a headcount range of 101-250, according to akta.pro [company records](https://akta.pro/company-data). The same records list a valuation estimate of $50 million-$100 million and Vishal Agrawal as Founder and CEO. The firm's repository holds 7000+ research reports across 27 therapeutic areas, and it has completed 500+ consulting projects.\n\n## Earlier DelveInsight Pipeline Reports\n\nDelveInsight released a report on October 29, 2026, covering 18+ companies and 22+ pipeline drugs in obstructive sleep apnea, GlobeNewswire reported. On October 27, 2026, the firm published a TGFb inhibitors report covering 25+ companies developing 30+ drugs, with about 18 in mid or early stages, GlobeNewswire reported. DelveInsight forecast growth in the BTK inhibitors market through 2036 on November 2, 2026, driven by rising B-cell malignancies and targeted therapy adoption, GlobeNewswire reported.\n\n## Agios and Mitapivat's FDA Date\n\nAgios Pharmaceuticals said in July 2026 that the FDA accepted its supplemental New Drug Application for mitapivat in sickle cell disease under Priority Review, with a PDUFA goal date of November 1, 2026. The submission was made under the FDA's accelerated approval pathway.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}